On November 18, 2024, Director David Ebsworth purchased 20,000 shares of Verona Pharma PLC (VRNA, Financial) at a price of $4.44 per share, as reported in the SEC Filing. Following this transaction, the insider now owns a total of 940,003 shares in the company.
Verona Pharma PLC is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases.
Over the past year, the insider has been actively increasing his stake in the company, purchasing a total of 95,360 shares. This recent acquisition is part of a broader trend observed within the company, where there have been 5 insider buys and 14 insider sells over the past year.
The stock's valuation metrics, such as the market cap of $3.115 billion and its trading price, provide a snapshot of the company's current market position. Additional valuation ratios like the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow are available for a deeper financial analysis.
For further insights into the insider's trading patterns and the overall insider transaction trends at Verona Pharma PLC, refer to the insider trend image below:
This insider activity could be a point of interest for investors and analysts following Verona Pharma PLC and assessing its GF Value and investment potential.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
